Zivo Bioscience (Zivo Bioscience) Cash-to-Debt : 0.18 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zivo Bioscience's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.18.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Zivo Bioscience couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Zivo Bioscience's Cash-to-Debt or its related term are showing as below:

ZIVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 40.92
Current: 0.18

During the past 13 years, Zivo Bioscience's highest Cash to Debt Ratio was 40.92. The lowest was 0.00. And the median was 0.03.

ZIVO's Cash-to-Debt is ranked worse than
92.45% of 1523 companies
in the Biotechnology industry
Industry Median: 6.46 vs ZIVO: 0.18

Zivo Bioscience Cash-to-Debt Historical Data

The historical data trend for Zivo Bioscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zivo Bioscience Cash-to-Debt Chart

Zivo Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.07

0.03

34.91

4.04

0.79

Zivo Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.22	0.01	0.99	0.79	0.18

Competitive Comparison of Zivo Bioscience's Cash-to-Debt

For the Biotechnology subindustry, Zivo Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zivo Bioscience's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zivo Bioscience's Cash-to-Debt falls into.

Zivo Bioscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zivo Bioscience's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.274	/	(0.346	+	0)
	=	0.79

Zivo Bioscience's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.139	/	(0.779	+	0)
	=	0.18

Zivo Bioscience (OTCPK:ZIVO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zivo Bioscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zivo Bioscience (Zivo Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304

Website

https://www.zivobioscience.com

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.

Executives

Alison A Cornell	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore	officer: CHIEF FINANCIAL OFFICER	4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson	director	768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne	director	9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando	officer: Chief Financial Officer	C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome	10 percent owner	100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P	10 percent owner	100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp	10 percent owner	100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc.	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc	10 percent owner	2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr	director	70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox	director	470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl	officer: President, CEO	7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young	other: See remarks below.	1800 NW CORPORATE BLVD, BOCA RATON FL 33431